Cited by 1,930Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBlood transfusion and management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Open access

Besarab, Anatole, Bolton, W. Kline, Browne, Jeffrey K., Egrie, Joan C., Nissenson, Allen R., Okamoto, Douglas M., Schwab, Steve J., Goodkin, David A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199808273390903

Open this paper in CoChat — free account Open PDF

Abstract

BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199808273390903

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
(1990) · BMJ · doi:10.1136/bmj.300.6724.573 · Cited by 427
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401

Show all 28 references

Research works printed but not linked: 8

Pascual J, 1991, Clin Nephrol, 35, 280
Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
Collins A, 1994, J Am Soc Nephrol, 5, 439
Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
Barany P, 1996, J Am Soc Nephrol, 7, 1472
Benz RL, 1996, J Am Soc Nephrol, 7, 1473
Hoen B, 1995, Nephrol Dial Transplant, 10, 377
Collins A, 1997, J Am Soc Nephrol, 8, 190A

Sorted by citations

Items 401–500 of 1,000

Potential cost savings of erythropoietin administration in end-stage renal disease
Hynes, D. M., Stroupe, K. T., Greer, J. W., Reda, D. J., Frankenfield, D. L., Kaufman, J. S., Henderson, W. G., Owen, W. F., Rocco, M. V., Wish, J. B., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01103-2 · Cited by 50
Intravenous iron for the treatment of predialysis anemia
Silverberg, D. S., Blum, M., Agbaria, Z., Schwartz, D., Zubkov, A., Yachnin, T., & Iaina, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69079.x · Cited by 50
Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients
Lee, S., Lee, H., Kim, Y., Kim, S. H., Kim, L., Lee, M. S., Joe, S.-H., Jung, I., Suh, K.-Y., & Kim, H.-K. (2004) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(03)00528-2 · Cited by 49
Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality
Garimella, P. S., Katz, R., Patel, K. V., Kritchevsky, S. B., Parikh, C. R., Ix, J. H., Fried, L. F., Newman, A. B., Shlipak, M. G., Harris, T. B., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002124 · Cited by 49
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data
Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H. M., Steenkamp, R. D., Tomson, C., et al. (2018) · American Journal of Nephrology · doi:10.1159/000493551 · Cited by 49
The High Prevalence of Anemia in Diabetes Is Linked to Functional Erythropoietin Deficiency
Thomas, M. C. (2006) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2006.05.003 · Cited by 49
Alternative Matrices for Therapeutic Drug Monitoring of Immunosuppressive Agents Using LC–MS/MS
Ghareeb, M., & Akhlaghi, F. (2015) · Bioanalysis · doi:10.4155/bio.15.35 · Cited by 48
Temporal Trends in Red Blood Transfusion Among US Dialysis Patients, 1992-2005
Ibrahim, H. N., Ishani, A., Foley, R. N., Guo, H., Liu, J., & Collins, A. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.022 · Cited by 48
Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
Hasegawa, T., Bragg‐Gresham, J. L., Pisoni, R. L., Robinson, B. M., Fukuhara, S., Akiba, T., Saitō, A., Kurokawa, K., & Akizawa, T. (2010) · Kidney International · doi:10.1038/ki.2010.382 · Cited by 48
The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review
Silverberg, D. S., Wexlerb, D., Iaina, A., & Schwartz, D. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.06.015 · Cited by 48
Anemia in patients of diabetic kidney disease
Tsai, S.-F., & Tarng, D. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000175 · Cited by 48
Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study
Tennankore, K., Soroka, S., West, K. A., & KIBERD, B. A. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-19 · Cited by 48
Anaemia in patients with diabetes: unrecognised, undetected and untreated?
Stevens, P. E., O'Donoghue, D. J., & Lameire, N. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002036 · Cited by 48
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties
Copland, I. B., Jolicoeur, M. E., Gillis, M., Cuerquis, J., Eliopoulos, N., Annabi, B., Calderone, A., Tanguay, J., Ducharme, A., & Galipeau, J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn090 · Cited by 48
Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations
Beddhu, S., Logar, C. M., & Herzog, C. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200304000-00008 · Cited by 48
Anemia management in patients with chronic renal insufficiency
Kausz, A. T., Obrador, G. T., & Pereira, B. J. G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19930 · Cited by 48
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials
Minutolo, R., Liberti, M. E., Simeon, V., Sasso, F. C., Borrelli, S., Nicola, L. D., & Garofalo, C. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad143 · Cited by 47
Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari, S., Alpert, M., & Aggarwal, K. B. (2014) · PubMed · Cited by 47
Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury
Johnson, A. C. M., Becker, K., & Zager, R. A. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00248.2010 · Cited by 47
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes
Zhang, Y., Thamer, M., Kaufman, J. S., Cotter, D. J., & Hernán, M. Á. (2011) · Kidney International · doi:10.1038/ki.2011.188 · Cited by 47
Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
Hung, S., Lin, Y., & Tarng, D. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.09.004 · Cited by 47
Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients
Kainz, A., Mayer, B., Kramar, R., & Oberbauer, R. W. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq287 · Cited by 47
The Labile Side of Iron Supplementation in CKD
Slotki, I. N., & Cabantchik, Z. I. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010052 · Cited by 47
Stimulating erythropoiesis in inflammatory bowel disease associated anemia
Tsiolakidou, G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i36.4798 · Cited by 47
Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose
Pai, A. B., Conner, T. A., McQuade, C. R., Olp, J., & Hicks, P. (2011) · BioMetals · doi:10.1007/s10534-011-9409-6 · Cited by 46
Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
Aapro, M., Gascón, P., Patel, K. B., Rodgers, G. M., Fung, S., Arantes, L. H., & Wish, J. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01498 · Cited by 46
How I treat renal anemia
Fishbane, S. N., & Coyne, D. W. (2020) · Blood · doi:10.1182/blood.2019004330 · Cited by 46
Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
Nakanishi, T., Kuragano, T., Kaibe, S., Nagasawa, Y., & Hasuike, Y. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0694-3 · Cited by 45
Blood disorders after kidney transplantation
Reindl‐Schwaighofer, R., & Oberbauer, R. W. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.10.001 · Cited by 45
Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g‐Formula to Anemia Management Strategies
Zhang, Y., Young, J. G., Thamer, M., & Hernán, M. Á. (2017) · Health Services Research · doi:10.1111/1475-6773.12718 · Cited by 45
Diabetic nephropathy and anaemia
Ritz, E., & Haxsen, V. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01544.x · Cited by 45
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Prasad, V. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70145-7 · Cited by 45
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects
Zheng, H., Huang, X., Zhang, Q., & Katz, S. D. (2006) · Kidney International · doi:10.1038/sj.ki.5000046 · Cited by 44
Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Karaboyas, A., Morgenstern, H., Fleischer, N. L., Vanholder, R. C., Dhalwani, N. N., Schäeffner, E., Schaubel, D. E., Akizawa, T., James, G., Sinsakul, M. V., et al. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.01.007 · Cited by 44
Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease
Mikhail, A. I., Shrivastava, R., & Richardson, D. (2011) · Nephron Clinical Practice · doi:10.1159/000328063 · Cited by 44
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study
Blohmer, J., Paepke, S., Sehouli, J., Boehmer, D., KOLBEN, M., Würschmidt, F., Petry, K. U., Kimmig, R., Elling, D., Thomssen, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4899 · Cited by 44
The clinical epidemiology of cardiovascular disease in chronic kidney disease
Shik, J., & Parfrey, P. S. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000170752.64150.88 · Cited by 44
Chronic Renal Dysfunction as an Independent Risk Factor for the Development of Cardiovascular Disease
Varma, R., Garrick, R., McClung, J. A., & Frishman, W. H. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000132600.45876.d0 · Cited by 44
Experience with a Large Dose (500 MG) of Intravenous Iron Dextran and Iron Saccharate in Peritoneal Dialysis Patients
Prakash, S., Walele, A., Dimkovic, N. B., Bargman, J. M., Vas, S. I., & Oreopoulos, D. G. (2001) · Peritoneal Dialysis International · doi:10.1177/089686080102100310 · Cited by 44
Low Hemoglobin Levels and Hypo‐Responsiveness to Erythropoiesis‐Stimulating Agent Associated With Poor Survival in Incident J apanese Hemodialysis Patients
Akizawa, T., Saitō, A., Gejyo, F., Suzuki, M., Nishizawà, Y., Tomino, Y., Tsubakihara, Y., Akiba, T., Hirakata, H., Watanabe, Y., et al. (2014) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12155 · Cited by 43
How important is transfusion avoidance in 2013?
Macdougall, I. C., & Obrador, G. T. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs575 · Cited by 43
The New FDA Labeling for ESA—Implications for Patients and Providers
Manns, B., & Tonelli, M. A. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09960911 · Cited by 43
Platelets in Advanced Chronic Kidney Disease: Two Sides of the Coin
Lutz, P. D. M. J., & Jurk, P. D. R. N. K. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1708841 · Cited by 43
A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps
Lopes, M. B., Tu, C., Zee, J., Guedes, M. H., Pisoni, R. L., Robinson, B. M., Foote, B. S., Hedman, K., James, G., Lopes, A. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79254-6 · Cited by 43
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne, D. W., Singh, A. K., Lópes, R. D., Bailey, C. K., Dimino, T. L., Huang, C., Connaire, J. J., Rastogi, A., Kim, S.-G., Orías, M., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00550122 · Cited by 43
Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients
Kaneko, Y., Miyazaki, S., Hirasawa, Y., Gejyo, F., & Suzuki, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00826.x · Cited by 43
Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization
Servilla, K. S., Singh, A. K., Hunt, W. C., Harford, A., Miskulin, D. C., Meyer, K. B., Bedrick, E. J., Rohrscheib, M. R., Tzamaloukas, A. H., Johnson, H., et al. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.05.007 · Cited by 43
The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?
Fishbane, S. N., & Nissenson, A. R. (2007) · Kidney International · doi:10.1038/sj.ki.5002401 · Cited by 43
Self-citation
Effect of erythropoietin on cardiovascular diseases
Sunder–Plassmann, G., & Hörl, W. H. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27391 · Cited by 43
Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD
Buren, P. N. V., Velez, R. L., Vaziri, N. D., & Zhou, X. J. (2011) · International Urology and Nephrology · doi:10.1007/s11255-011-0028-5 · Cited by 42
Left ventricular dysfunction in the haemodialysis population
Sood, M. M., Pauly, R. P., Rigatto, C., & Komenda, P. V. J. (2008) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfn074 · Cited by 42
Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01119.x · Cited by 42
Erythropoietin: physiology and molecular mechanisms
Foley, R. N. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9083-0 · Cited by 42
Calcimimetics in chronic kidney disease: evidence, opportunities and challenges
Evenepoel, P. (2008) · Kidney International · doi:10.1038/ki.2008.166 · Cited by 42
Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease
Berns, J. S., Rudnick, M. R., Cohen, R. M., Bower, J. D., & Wood, B. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00531.x · Cited by 42
Editorial Focus: Thrombosis with Erythropoietic Stimulating Agents—Does Iron‐Deficient Erythropoiesis Play a Role?
Dahl, N. V., Henry, D. H., & Coyne, D. W. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00435.x · Cited by 42
CONFERENCE REPORT: Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
Shander, A., Spence, R. K., & Auerbach, M. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02492.x · Cited by 41
Erythropoietin Protects Critically Perfused Flap Tissue
Rezaeian, F., Wettstein, R., Amon, M., Scheuer, C., Schramm, R., Menger, M. D., Pittet, B., & Harder, Y. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31818f678e · Cited by 41
The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure
Chait, Y., Kalim, S., Horowitz, J., Hollot, C. V., Ankers, E. D., Germain, M. J., & Thadhani, R. (2016) · Hemodialysis International · doi:10.1111/hdi.12407 · Cited by 41
Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review
Murali, K., Mullan, J., Chen, J. H. C., Roodenrys, S. J., & Lonergan, M. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0449-1 · Cited by 41
Arteriovenous fistulas for hemodialysis: Brief review and current problems
Manov, J. J., Mohan, P. P., & Vázquez-Padrón, R. I. (2021) · The Journal of Vascular Access · doi:10.1177/11297298211007720 · Cited by 41
The case for intervention bias in the practice of medicine.
Foy, A., & Filippone, E. J. (2013) · Europe PMC (PubMed Central) · Cited by 41
G‐Estimation and Artificial Censoring: Problems, Challenges, and Applications
Joffe, M. M., Yang, W. P., & Feldman, H. I. (2011) · Biometrics · doi:10.1111/j.1541-0420.2011.01656.x · Cited by 41
Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Pendse, S. S., & Singh, A. K. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.12.004 · Cited by 41
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
Smith, S. W., Sato, M., Gore, S. D., Baer, M. R., Xu, K., McNally, D. L., & Davidoff, A. J. (2011) · Haematologica · doi:10.3324/haematol.2011.051755 · Cited by 41
The Kidney Disease: Improving Global Outcomes website: Comparison of guidelines as a tool for harmonization
Vanbelleghem, H., Vanholder, R. C., Levin, N. W., Becker, G. J., Craig, J. C., Ito, S., Lau, J., Locatelli, F., Zoccali, C., Solez, K., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002177 · Cited by 41
Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients
Hanafusa, N., Nomura, T., Hasegawa, T., & Nangaku, M. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu272 · Cited by 41
Quality of life for patient groups
Jofre, R., López–Gómez, J. M., & Valderrábano, F. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07420.x · Cited by 41
Economic evaluation and end-stage renal disease: From basics to bedside
Manns, B., Taub, K. J., & Donaldson, C. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8235 · Cited by 41
Erythropoietic Stimulating Agents and Quality of a Patient’s Life
Kliger, A. S., Fishbane, S. N., & Finkelstein, F. O. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11961111 · Cited by 40
Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?
Vaziri, N. D. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0847 · Cited by 40
Influence of Progressive Renal Dysfunction in Chronic Heart Failure
Maxwell, A. P., Ong, H. Y., & Nicholls, D. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00238-0 · Cited by 40
The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions
Silverberg, D. S., Wexler, D., Iaina, A., & Schwartz, D. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0074-1 · Cited by 40
Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy
Foley, R. N., Curtis, B. M., & Parfrey, P. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02100508 · Cited by 40
CERA: third-generation erythropoiesis-stimulating agent
Topf, J. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.5.839 · Cited by 40
The relationship of haemoglobin level and survival: direct or indirect effects?
Levin, A. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_5.8 · Cited by 40
Erythropoietin and Treatment of Non-anemic Conditions—Cardiovascular Protection
Fliser, D., & Haller, H. G. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.008 · Cited by 40
Proteinuria as a surrogate end point—more data are needed
Thompson, A. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.43 · Cited by 39
Advancements in anemias related to chronic conditions
Guidi, G. C., & Santonastaso, C. L. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.264 · Cited by 39
Iron dosing in kidney disease: inconsistency of evidence and clinical practice
Gaweda, A. E., Ginzburg, Y. Z., Chait, Y., Germain, M. J., Aronoff, G. R., & Rachmilewitz, E. A. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu104 · Cited by 39
The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry
Maruyama, Y., Yokoyama, K., Yokoo, T., Shigematsu, T., Iseki, K., & Tsubakihara, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143430 · Cited by 39
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Baigent, C., & Lennon, R. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017101062 · Cited by 39
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease
Vecchio, L. D., & Locatelli, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1493455 · Cited by 39
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
Coyne, D. W., Singh, H. N., Smith, W. T., Giuseppi, A. C., Connarn, J. N., Sherman, M. L., Dellanna, F., Malluche, H. H., & Hruska, K. A. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.08.001 · Cited by 39
An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD
Clement, F. M., Klarenbach, S. W., Tonelli, M. A., Wiebe, N., Hemmelgarn, B. R., & Manns, B. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.07.015 · Cited by 39
Drug-Induced Cardiovascular Disorders
Murphy, C. A., & Dargie, H. J. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00005 · Cited by 39
RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
Provenzano, R., Fishbane, S. N., Szczech, L. A. M., Leong, R., Saikali, K. G., Zhong, M., Lee, T. T., Houser, M. T., Frison, L., Houghton, J., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.12.018 · Cited by 38
Retracted
Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health
Tomey, M. I., & Winston, J. A. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.007 · Cited by 38
Change in quality of life and one-year mortality risk in maintenance dialysis patients
Liebman, S. E., Li, N.-C., & Lacson, E. K., Jr. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1257-y · Cited by 38
Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM‐HD Study
Kuo, K., Hung, S., Tseng, W., Tsai, M., Liu, J., Lin, M., Hsu, C., Tarng, D., the Taiwan Society of Nephrology Renal Registry Data System, Ou, S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009206 · Cited by 38
How I treat anemia in heart failure
Anand, I. S., & Gupta, P. (2020) · Blood · doi:10.1182/blood.2019004004 · Cited by 38
Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward
Wolf, M. S., & Thadhani, R. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.11.009 · Cited by 38
Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis
Zhou, J., Wei‐jie, Y., Zhu, N., Zhou, Y., & Wang, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043655 · Cited by 38
Cardiovascular Complications in Diabetic Kidney Disease
Patel, T. V., & Charytan, D. M. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00704.x · Cited by 37
Clinical Outcomes With Use of Erythropoiesis Stimulating Agents in Patients With the HeartMate II Left Ventricular Assist Device
Nassif, M. E., Patel, J. S., Shuster, J. E., Raymer, D. S., Jackups, R., Novak, E. L., Gage, B. F., Prasad, S. M., Silvestry, S., Ewald, G. A., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.005 · Cited by 37
Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis
Kałaska, B., Sokołowska, E., Kamiński, K., Szczubiałka, K., Kramkowski, K., Mogielnicki, A., Nowakowska, M., & Buczko, W. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.037 · Cited by 37
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G‐CSF and novel agents
Nicholas, R. M., & NORRIS, S. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04269.x · Cited by 37
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Wang, C., Kane, R. C., Levenson, M. S., Kelman, J. A., Wernecke, M., Lee, J., Kozlowski, S., Dekmezian, C., Zhang, Z., Thompson, A., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6520 · Cited by 37
Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease
Finkelstein, F. O., van Nooten, F. E., Wiklund, I. E., Trundell, D., & Cella, D. F. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0933-8 · Cited by 37
Darbepoetin for the anaemia of chronic kidney disease
Palmer, S. C., Saglimbene, V. M., Craig, J. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009297.pub2 · Cited by 37

Authors: Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
Affiliations: Henry Ford Hospital (US)
University of Virginia Health System (US)
Amgen (United States) (US)
University of California, Los Angeles (US)
Duke University (US)
ORCID: Bolton, W. Kline
Goodkin, David A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-08-27
Volume: 339
Issue: 9
Pages: 584-590
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199808273390903
OpenAlex: W2331665138
Cited by: 1,930
References: 28
Citations by year: 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
FWCI: 21.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords: hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks